THERAPY DOSSIER · th-d53db0a08eb6

Interferon beta-1b

Biologic · Interferon alpha/beta receptor agonist

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Interferon alpha/beta receptor agonist
Target: CHEMBL2364170
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: 1993
Development stage: Not recorded
ChEMBL record: CHEMBL1201563 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: BAY 86-5046; BAY-86-5046; Betaferon; Betaseron; Extavia; Interferon beta-1b
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01701856 ↗PHASE4terminated

Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Enrolment: 5 · Results not recorded

NCT00202995 ↗PHASE4terminated

Study to Compare the Efficacy, Tolerability and Safety of Copaxone to High Dose Interferon (Betaseron or Rebif) in Relapsing Multiple Sclerosis Patients

Relapsing Remitting Multiple Sclerosis

Enrolment: 91 · Results not recorded

NCT00185211 ↗PHASE3completed

Long-term Follow-up Extension of the BENEFIT Study of Interferon Beta-1b (Betaferon/Betaseron)

Multiple Sclerosis

Enrolment: 468 · Results not recorded

NCT01432704 ↗PHASE2/PHASE3completed

Phase IV Study of Colecalciferol as an add-on Treatment to Interferon-beta-1b for Treatment of MS

Multiple Sclerosis

Enrolment: 70 · Results not recorded

NCT04343768 ↗PHASE2completed

An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b in Moderate to Severe COVID-19

COVID-19

Enrolment: 60 · Results not recorded

NCT03347370 ↗NAcompleted

Subcutaneous Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms

Multiple Sclerosis, Relapsing-Remitting

Enrolment: 626 · Results not recorded

NCT00902135 ↗NAcompleted

Betaferon Injection Management: Non-interventional Study on PDA Supported Effects on Adherence (BETAPATH)

Relapsing-Remitting Multiple Sclerosis

Enrolment: 702 · Results not recorded

NCT02749396 ↗NAcompleted

Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon beta - a Register-based Study in the Nordic Countries

Multiple Sclerosis

Enrolment: 2089 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23344866 ↗2013Reported benefit

Neuroprotective effect of acute interferon-beta 1B treatment after spinal cord injury.

RatSpinal cord injuryContusionSprague-DawleyMalen = 24 rats in 3 groupsAfter injury (acute treatment); exact interval not stated

Model: Weight-drop contusion spinal cord injury

Interferon beta-1b increased tissue heat shock protein 70 and reduced leucocyte infiltration, haemorrhage, oedema and necrosis compared with saline and control groups.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…